Abstracts tagged "Effective"

Abstract Number: 2049 • 2015 ACR/ARHP Annual Meeting
Long Term Effectiveness of Herpes Zoster Vaccine Among Patients with Autoimmune and Inflammatory Diseases
Huifeng Yun¹, Fenglong Xie², John Baddley³, Kevin L. Winthrop⁴, Lang Chen⁵ and Jeffrey R. Curtis⁶, ¹Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ²Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ³Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁴Oregon Health and Science University, Portland, OR, ⁵University of Alabama at Bimingham, Birmingham, AL, ⁶University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The live herpes zoster (HZ) vaccine is effective in healthy older people to reduce the incidence and burden of HZ. Recent results from a…
Abstract Number: 2611 • 2014 ACR/ARHP Annual Meeting
Short Term Efficacy of Tumor Necrosis Factor Inhibitors in Patients with non–radiographic Axial Spondylarthritis and ankylosing Spondylitis; Results from Turkbio Registry
Pinar Cetin¹, Umut Kalyoncu², Bunyamin Kisacik³, Ismail Sari¹, Dilek Solmaz⁴, Omer Karadag², Ahmet Mesut Onat³, Gezmis Kimyon⁵, Levent Kilic⁶, Fatos Onen¹, Sedat Kiraz², Merih Birlik¹, Ihsan Ertenli², Omer Nuri Pamuk⁷ and Nurullah Akkoc¹, ¹Rheumatology, Dokuz Eylul University School of Medicine, Izmir, Turkey, ²Rheumatology, Hacettepe University School of Medicine, Ankara, Turkey, ³Rheumatology, Gaziantep University School of Medicine, Gaziantep, Turkey, ⁴Department of Internal Medicine, Division of Rheumatology, Namik Kemal University School of Medicine, Tekirdag, Turkey, ⁵Department of Rheumatology, Gaziantep University School of Medicine, Gaziantep, Turkey, ⁶Rheumatology, HacettepeUniversity School of Medicine, Ankara, Turkey, ⁷Department of Rheumatology, Trakya University School of Medicine, Edirne, Turkey
Background/Purpose Axial spondylarthritis (AxSpA) has been proposed as an umbrella term for ankylosing spondylitis (AS) and non-radiographic (nr) AxSpA). This new concept makes diagnosis of…
Abstract Number: 2478 • 2014 ACR/ARHP Annual Meeting
Analysis of the Clinical Sustained Response after Retreatment with a Lower Dose of Rituximab in Patients with Chronic Inflammatory Arthropathies
M. Victoria Hernández¹, Andrea Cuervo¹, Sonia Cabrera¹, Jose Inciarte-Mundo¹, Julio Ramirez¹, Virginia Ruiz-Esquide¹, Juan D. Cañete² and Raimon Sanmarti¹, ¹Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ²Rheumatology, Hospital Clinic, Barcelona, Spain
Background/Purpose: The dosage of rituximab (RTX) approved for the treatment of active rheumatoid arthritis (RA) is two intravenous (iv.) 1 g infusions, separated by two…
Abstract Number: 1868 • 2014 ACR/ARHP Annual Meeting
Can DAS 28 at 3 Months after the 1^st Biologic Therapy Predict Subsequent Sustainable Clinical Remission in Polyarticular Juvenile Idiopathic Arthritis Patients?
Tomohiro Kubota¹, Syuji Takei², Tsuyoshi Yamatou³, Tomokazu Nagakura⁴, Hiroyuki Imanaka³, Yukiko Nonaka³, Tomoko Takezaki³, Harumi Akaike³ and Mio Matsuura⁵, ¹8-35-1 Sakuragaoka, Kagoshima University Hospital, Kagoshima City, Japan, ²School of Health Sciences, Faculty of Medicine, Kagoshima University, Kagoshima, Japan, ³Department of Pediatrics, Kagoshima University Hospital, Kagoshima, Japan, ⁴Department of Pediatrics, House of Meguminoseibo, Usuki, Japan, ⁵Kagoshima University, Kagoshima-Shi, Japan
Background/Purpose: To avoid the progression of joint damage, early decision making is important in JIA patients who failed to achieve sustainable clinical remission by…
Abstract Number: 1532 • 2014 ACR/ARHP Annual Meeting
Efficacy of the Subcutaneous Formulation of Abatacept/Orencia in Rheumatoid Arthritis, a Single-Center Italian Experience
Rossella Reggia¹, Franco Franceschini¹, Angela Tincani² and Ilaria Cavazzana¹, ¹AO Spedali Civili, Rheumatology and Clinical Immunology Unit, Brescia, Italy, ²Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy
Background/Purpose Abatacept is a selective T cell costimulation modulator indicated for moderately to severely active Rheumatoid Arthritis (RA). Since August 2013 is available in Italy…
Abstract Number: 481 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety of Etanercept in Rheumatoid Arthritis Patients over 75 Years Old
Satoru Kodama, Satoshi Ito, Akira Murasawa, Kiyoshi Nakazono and Daisuke Kobayashi, Niigata Rheumatic Center, Shibata, Japan
Background/Purpose Early introductions of biologics in early rheumatoid arthritis (RA) patients are well documented, but there are few reports of biologics use in established elderly…
Abstract Number: 856 • 2013 ACR/ARHP Annual Meeting
Cost-Effectiveness Of Urate Lowering Strategies For The Management Of Gout
Eric Jutkowitz¹, Karen Kuntz², Laura T Pizzi³ and Hyon Choi^4,5, ¹Divisions of Health Policy and Management (EJ, KMK), School of Public Health, University of Minnesota, Minneapolis, MN, ²Division of Health Policy and Management, School of Public Health, University of Minnesota, Minneapolis, MN, ³Thomas Jefferson University, Philadelphia, PA, ⁴Section of Rheumatology and the Clinical Epidemiology, Boston University School of Medicine, Boston, MA, ⁵Division of Rheumatology, Allergy, and Immunology Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: The new 2012 ACR guidelines for the management of gout have provided updated recommendations; however, the employed method do not address the societal costs…
Abstract Number: 426 • 2013 ACR/ARHP Annual Meeting
Characteristics of Protocol-Specified Responders/Non-Responders Treated With Etanercept Plus Methotrexate in Period 1 of the Prize Study
Paul Emery¹, Annette Szumski², Jack Bukowski³, Eustratios Bananis² and Lisa Marshall⁴, ¹Institute Rheumatic and Musculoskeletal Medicine University of Leeds, Leeds, United Kingdom, ²Specialty Care, Pfizer Inc., Collegeville, PA, ³Department of Specialty Care, Pfizer Inc, Collegeville, PA, ⁴Pfizer Inc., Collegeville, PA
Background/Purpose: Although frequently effective, treatment with synthetic or biologic disease-modifying antirheumatic drugs (DMARDs) does not adequately control disease activity in all patients. Prompt identification of…
Abstract Number: 355 • 2013 ACR/ARHP Annual Meeting
Response To Etanercept With Or Without Methotrexate Combination Therapy In Patients With Psoriatic Arthritis
Bernard Combe¹, Urs Kerkmann², Fiona Brock³ and Gaia Gallo², ¹Hôpital Lapeyronie-Service d'Immuno-rhumatologie, Montpellier, France, ²Pfizer Europe, Rome, Italy, ³Quanticate, Hitchin, Hertfordshire, United Kingdom
Background/Purpose: Randomized controlled trials in psoriatic arthrtitis (PsA) have allowed treatment with TNF inhibitors (TNFi) as monotherapy as well as co-medication with methotrexate (MTX), but…
Abstract Number: 281 • 2013 ACR/ARHP Annual Meeting
GO-Kids Imaging Substudy: MRI Treatment Response To 30 Mg/m² 4-Weekly Subcutaneous injections Of Golimumab In Children With Polyarticular JIA – Preliminary Results Of The Open Label Portion
Nikolay Tzaribachev¹, Catrin Tzaribachev¹ and Bernd Koos², ¹Pediatric Rheumatology, PRI - Pediatric Rheumatology Research Institute, Bad Bramstedt, Germany, ²Clinic of Orthodontics, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany
GO-KIDS Imaging Substudy: MRI treatment response to 30 mg/m2 4-weekly subcutaneous injections of Golimumab in children with polyarticular JIA– preliminary results of the open label…
Abstract Number: 276 • 2013 ACR/ARHP Annual Meeting
Assessment Of Radiographic Progression In Patients With Systemic Juvenile Idiopathic Arthritis Treated With Tocilizumab: 2-Year Results From The Tender Trial
Clara Malattia¹, Nicolino Ruperto¹, Elena Palmisani¹, Silvia Pederzoli¹, Angela Pistorio¹, Hermine Brunner², Rubén J. Cuttica³, Inmaculada Calvo¹, Stella Maris Garay¹, Despina Eleftheriou¹, Carine Wouters¹, Jianmei Wang⁴, Clare Devlin⁴, Daniel J. Lovell², Alberto Martini⁵, Fabrizio De Benedetti⁶ and Angelo Ravelli⁵, ¹PRINTO, Genoa, Italy, ²PRCSG, Cincinnati, OH, ³Hospital de Niños Pedro de Elizalde - University of Buenos Aires, Buenes Aires, Argentina, ⁴Roche Products Ltd., Welwyn Garden City, United Kingdom, ⁵Pediatria II, Istituto Giannina Gaslini, Genova, Italy, ⁶IRCCS Ospedale Pediatrico Bambino Gesú, Rome, Italy
Background/Purpose: A phase 3 trial (TENDER) demonstrated the efficacy of the interleukin-6 receptor inhibitor tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (sJIA).1,2 The…
Abstract Number: 2628 • 2013 ACR/ARHP Annual Meeting
Immunogenicity Of Infliximab Modulates Efficacy and Safety In Behcet’s Disease Patients With Uveitis
Mitsuhiro Takeno¹, Kayo Terauchi¹, Yohei Kirino^1,2, Ryusuke Yoshimi¹, Nobuhisa Mizuki², Etsuko Shibuya³ and Yoshiaki Ishigatsubo², ¹Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ²Yokohama City University Graduate School of Medicine, Yokohama, Japan, ³Department of Ophthalmology and Visual Science, Yokohama City University Graduate School of Medicine, Yokohama, Japan
Background/Purpose: Infliximab (IFX) suppresses ocular attacks in Behcet’s disease (BD) with uveitis, resulting in favorable long-term visual prognosis. However, some patients had ocular attacks which…
Abstract Number: 2384 • 2013 ACR/ARHP Annual Meeting
Variability In Patient Characteristics and Outcomes In Rheumatoid Arthritis Upon Infliximab Treatment Based On The Size Of Biologic Treatment Registry Site
J. Carter Thorne¹, William G. Bensen², Sanjay Dixit³, Rafat Y. Faraawi^3,4, Dalton E. Sholter⁵, Maqbool K. Sheriff⁶, Philip Baer⁷, Denis Choquette⁸, Boulos Haraoui^8,9, Algis Jovaisas¹⁰, Emmanouil Rampakakis^11,12, John S. Sampalis^11,12, May Shawi¹³, Francois Nantel¹⁴, Allen J. Lehman¹⁵ and Susan M. Otawa¹⁵, ¹Southlake Regional Health Centre, Newmarket, ON, Canada, ²Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, ³McMaster University, Hamilton, ON, Canada, ⁴Rheumatologist, KW Musculoskeletal Research Inc., Kitchener, ON, Canada, ⁵Rheumatology Associates, Edmonton, AB, Canada, ⁶Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁷Private Practice, Scarborough, ON, Canada, ⁸Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ⁹Department of Medicine, Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada, ¹⁰Division of Rheumatology, University of Ottawa, Ottawa, ON, Canada, ¹¹JSS Medical Research, Montreal, QC, Canada, ¹²Jewish General Hospital, McGill University, Montreal, QC, Canada, ¹³Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada, ¹⁴Janssen Inc., Toronto, ON, Canada, ¹⁵Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Efficacy of TNFi agents in the management of rheumatoid arthritis (RA) has been demonstrated in numerous controlled clinical trials. Variations with respect to patient…
Abstract Number: 1550 • 2013 ACR/ARHP Annual Meeting
Validation Of The Ankylosing Spondylitis Disease Activity Score and Effectiveness Of Infliximab In The Treatment Of Ankylosing Spondylitis Over 4 Years: The Canadian Experience
Proton Rahman¹, Denis Choquette², Majed M. Khraishi³, William G. Bensen⁴, Saeed A. Shaikh⁵, Dalton E. Sholter⁶, Maqbool K. Sheriff⁷, Emmanouil Rampakakis⁸, John S. Sampalis⁸, Francois Nantel⁹, Susan M. Otawa¹⁰, Allen J. Lehman¹⁰ and May Shawi¹¹, ¹Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ²Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ³Nexus Clinical Research, St John's, NF, Canada, ⁴Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, ⁵Medicine, McMaster University, St Catharines, ON, Canada, ⁶Rheumatology Associates, Edmonton, AB, Canada, ⁷Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁸JSS Medical Research, Montreal, QC, Canada, ⁹Janssen Inc., Toronto, ON, Canada, ¹⁰Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹¹Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada
Background/Purpose: The efficacy of anti-TNF in the management of Ankylosing Spondylitis (AS) has been demonstrated in numerous controlled clinical trials. The objective of this study…
Abstract Number: 1528 • 2013 ACR/ARHP Annual Meeting
Patient-Tailored Dose Reduction Of Tumor Necrosis Factor-Alpha Blocking Agents In Ankylosing Spondylitis Patients With Stable Low Disease Activity
Suzanne Arends^1,2, Eveline van der Veer³, Fleur B.S. Kamps⁴, Monique Efde², Martha K. Leijsma⁴, Hendrika Bootsma¹, Elisabeth Brouwer⁵ and Anneke Spoorenberg^2,4, ¹Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ²Rheumatology, Medical Center Leeuwarden, Leeuwarden, Netherlands, ³Laboratory Medicine, University Medical Center Groningen, Groningen, Netherlands, ⁴Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ⁵Dept. of Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Tumor necrosis factor-alpha (TNF-α) blocking agents are very effective in controlling inflammation and improving clinical assessments in patients with ankylosing spondylitis (AS). In view…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].